



HM2024-11: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA-R-CHP) VERSUS POLATUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over This study is NOT accepting healthy

volunteers

Inclusion Criteria:

- 18 to 80 years old - have not received any treatment for Large B-Cell Lymphoma - able to walk and do all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- prior solid organ transplantation - history of significant cardiovascular disease - current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease - clinically significant liver disease - chronic hepatitis B infection, hepatitis C, or HIV

Conditions & Interventions

Interventions:

Drug: Cyclophosphamide, Drug: Doxorubicin, Drug: Glofitamab, Drug: Polatuzumab vedotin, Drug: Prednisone, Drug: Rituximab

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Large B-Cell Lymphoma, LBCL, lymphoma

More Information

Description: The purpose of this study is to compare the efficacy and safety of glofitamab, a novel cluster of differentiation (CD) 20/CD3 bispecific antibody, in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus Pola-R-CHP in patients with previously untreated CD20-positive large B-cell lymphoma (LBCL).

Study Contact: Sanjal Desai - desai171@umn.edu

Principal Investigator: Sanjal Desai

Phase: PHASE3

IRB

Number: STUDY00022042

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.